CD274 and extranodal nasal NK/T cell lymphoma: However, more than 40% of patients experience treatment failure.1 Relapsed/refractory patients had poor survival with a median progress-free survival (PFS) of 4.1 months and overall survival (OS) of 6.4 months.2 Immune checkpoint inhibitors (ICIs) have shown promising efficacy in NKTCL as NKTCL has a higher expression of PD-L1 induced by EBV infection and escapes the immune surveillance.3 However, upon their failure, there is no effective salvage treatment, and the prognosis is extremely poor.